What Janssen hopes to achieve with first disease interception trial in Type I diabetes
The first clinical trial to come from the Janssen Research & Development LLC's Disease Interception Accelerator will move upstream from the way Type I diabetes is treated today, even if it doesn't directly prevent the disease, and help parent company Johnson & Johnson build a new hypothesis about how to prevent or delay its onset.
Janssen is already exploring disease interception within its core therapeutic areas, and previously told BioCentury that it plans to begin a trial to intercept inflammatory bowel disease (IBD) in 2017.
The diabetes trial is the first to come from the DIA, a group launched last year dedicated to exploring ways to interrupt the transition from health to disease. So far the group has announced research programs